Moore Capital Management’s 10x Genomics TXG Stock Holding History

Moore Capital Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-54,216	Closed	-$634K	–	828
2025 Q3	$634K	Sell	54,216 -24,552	-31%	-$320K	0.01%	464
2025 Q2	$912K	Sell	78,768 -131,462	-63%	-$1.2M	0.01%	389
2025 Q1	$1.84M	Buy	+210,230	New	+$2.65M	0.04%	274
2023 Q2	–	Sell	-50,000	Closed	-$2.79M	–	595
2023 Q1	$2.79M	Buy	+50,000	New	+$2.33M	0.06%	211

Other funds holding TXG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Moore Capital Management's TXG Position: Q4 2025 in Review

Moore Capital Management sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 54,216 shares — an estimated $634K sold.

Moore Capital Management first reported a position in TXG in Q1 2023 and held it in 4 quarters. The position peaked at $2.79M in Q1 2023. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

Moore Capital Management reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
Moore Capital Management sold 54,216 10x Genomics shares in Q4 2025, an estimated $634K.
Moore Capital Management first reported a position in 10x Genomics in Q1 2023 and held it in 4 quarters.
Moore Capital Management's 10x Genomics position peaked at $2.79M in Q1 2023.
322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Moore Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.